Related investing topics
About the Author
Jon Quast has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, Intuitive Surgical, Nvidia, and Tesla. The Motley Fool has a disclosure policy.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
Neuralink is a high-profile medical device start-up founded by Elon Musk that’s developing brain-computer interface technology with potentially far-reaching applications, and investors are excited for the chance to own Neuralink stock.
The company’s implant, called N1, is designed to read brain signals and transmit them to computers. Neuralink initially aims to help people with paralysis regain mobility and restore vision for those with visual impairments. While brain-computer interfaces aren’t entirely new, Neuralink’s approach could push the technology forward.
Neuralink conducted its first human implant in early 2024, and by September 2025, 12 patients had received the device.

Neuralink is not publicly traded. When businesses go public, they offer shares to retail investors on stock exchanges either through an initial public offering (IPO) or a direct listing. But Neuralink hasn't done either as of this writing.
To be clear, private companies like Neuralink can still have a share structure. Founders, insiders, and private investors can all own pieces of the business, and this is true of Neuralink.
Neuralink has done several funding rounds, most recently in June 2025 when it raised $650 million from investment firms in a Series E funding round. These private investors now own shares of Neuralink, although Musk, as the founder, is still believed to be the largest shareholder.
Occasionally, Neuralink shares trade hands in private transactions. However, only accredited investors can participate in these trades.
There hadn't been any formal announcements regarding the timing of a Neuralink IPO as of late 2025, so it's not on the IPO calendar. But it's fair to assume that it won't go public anytime soon.
Consider another private company owned by Musk: SpaceX. SpaceX is set to go public at a valuation that could reach $2 trillion, orders of magnitude more than Neuralink. Neuralink is much smaller, reportedly valued at closer to $9 billion as of its latest funding round. Neuralink's valuation would likely have to get significantly higher for the company to go public.
When Neuralink finally decides to go public, it won't come as a total surprise. IPO stocks file paperwork with the Securities and Exchange Commission (SEC) before offering shares to the public, so investors will be aware of any Neuralink IPO before it happens.
Neuralink is a private company, and its financials aren't publicly available. That said, it's very safe to assume that the company is not profitable.
Losses are common among medical device start-up companies. These businesses have to build out a technology and demonstrate its effectiveness before commercialization can begin. It's a stage in which companies such as Neuralink spend tons of money on research and development, as well as on sales and marketing. And during this phase, the company has almost no revenue because it has few (if any) customers.
While trials are expected to accelerate in the coming years after starting in 2024, they will likely generate minimal revenue, at best, and will likely be unprofitable -- the early-stage goal is proof of concept. Only after years of successful trials would the business have an opportunity to be profitable.
At this point, the company is targeting $1 billion in revenue by 2031, but that is still a far-off projection.
Here are some ideas for similar companies to Neuralink.
Buying shares of tech titan Alphabet (GOOG +1.90%)(GOOGL +2.01%) may be the best indirect way to invest in Neuralink. The company has its own venture capital arm called Google Ventures, which is an early investor in Neuralink.
Given its stake in the start-up, Neuralink technically comprises a part of Alphabet. That said, it's a minuscule stake compared to the overall size of Alphabet's business.
Getting a stake in Neuralink by investing in Tesla (TSLA -0.90%) stock is an immensely speculative long shot, at best. In 2022, an analyst asked Musk if he would ever consider lumping all of his companies, including Tesla and Neuralink, into one publicly traded entity. Musk said he was unsure and that he saw no reason to combine the companies soon.
It seems incredibly unlikely that Neuralink and Tesla would ever be housed under one parent company. But Musk didn't completely rule it out when directly asked. Even without Neuralink, investing in Tesla will give you exposure to Musk's best-known and the growth potential therein.
Medtronic is a leading medical device company, and it makes sense to look to that industry for an alternative to Neuralink. Medtronic is integrating Brain-Computer Interface (BCI) into its clinical therapies and neurosurgical systems, including for diseases like Parkinson's.
It's also partnered with Precision Neuroscience to use its cortical interface in one of its surgical systems.
BCI is still an emerging technology, but Medtronic has established itself as a leader. If you're looking for exposure to BCI, Medtronic is a great way to get it.
To buy Alphabet, Tesla, or any other public stock, investors will need to follow a few steps.
For investors interested in Neuralink stock because they like the themes of robotic surgery and AI, The Global X Robotics & Artificial Intelligence ETF (BOTZ -1.30%) may be one to consider. Top stocks in this ETF include Nvidia (NVDA -2.90%) and Intuitive Surgical (ISRG +1.20%).
This is just speculation, but if Neuralink really can restore mobility and vision, then other players in this field would likely emerge, focusing on different problems. Consider that prominent billionaires Jeff Bezos and Bill Gates have both invested in Synchron, a Neuralink peer.
A company like Intuitive Surgical, for example, may eventually be in a position to benefit from new trends pushed forward by advances in brain-computer interface technology. But that's likely still years away.
Neuralink believes it can restore lost mobility and vision through its brain-computer interface technology. These are big issues that could potentially make Neuralink a huge business in the future.
However, for now, the company isn't public, so investors can't buy stock. Even if it were public, it would still be a speculative investment opportunity, and shareholders would need a healthy appreciation of risk.